Analysis of differential expression of protease-activated receptors in patients with allergic fungal rhinosinusitis

Shikhar Sawhney, M.S.,¹ Sandeep Bansal, M.S.,¹ Madhur Kalyan, M.Sc.,² Indu Verma, Ph.D.,² Ramandeep Singh Virk, M.S.,¹ and Ashok Kumar Gupta, M.S.¹

ABSTRACT

Background: Ever since its characterization in the 1970s, allergic fungal rhinosinusitis (AFRS) has been the subject of much controversy, especially regarding its pathogenesis. In this study, we analyzed the differential expression of genes that encode protease-activated receptors (PAR) in patients with AFRS and patients with chronic rhinosinusitis, and tried to understand the pathogenic basis of this disease.

Objective: To analyze the differential expression of PAR genes in patients with AFRS and in patients with chronic rhinosinusitis.

Methods: Mucosa from ethmoid sinuses of 51 patients (tests and controls) was biopsied and evaluated for messenger RNA expression of PAR genes by using reverse transcriptase–polymerase chain reaction. Each of the four PAR genes, i.e., par1, par2, par3 and par4 was amplified, the final gene products were run on 1.8% agarose gel and analyzed by densitometry to calculate differential expression. The significance level was determined as p ≤ 0.05.

Results: It was observed that the expressions of all four par genes were higher in the test samples compared with the controls, but statistical significance was achieved only for par1 (p = 0.004) and par2 (p = 0.05). Comparative expression of the four PAR genes was also performed within the test and control groups, and a statistically significant difference was seen between par1 and par2 (p = 0.007), par1 and par3 (p = 0.029), par1 and par4 (p = 0.0001), par2 and par4 (p = 0.002), and par3 and par4 (p = 0.009) in the test group. In the control group as well, par1, par2, and par3 exhibited a higher expression compared with par4 but the difference was significant between par3 and par4 genes only.

Conclusion: Patients with AFRS expressed increased levels of PAR genes in their nasal mucosa, and, of the four PAR genes, a higher expression of par1, par2, and par3 was observed in both the groups compared with par4. This information contributes toward our understanding of pathogenesis and possibly treatment of AFRS.

(Allergy Rhinol 9:1–8, 2018; doi: 10.1177/2152656718764199)

Allergic fungal rhinosinusitis (AFRS) is a term introduced by Robson et al.¹ in 1989 to describe a constellation of unusual findings in a group of patients with chronic sinusitis. AFRS is a truly unique pathologic entity, defined largely by the presence of allergic fungal mucin, which is a thick green-to-gray lamellate of dense inflammatory cells, mostly eosinophils, in various stages of degranulation, Chacot-Leyden crystals, and fungal hyphae.² Since its initial characterization in the 1970s, AFRS has been the subject of much debate, controversy, and research regarding its etiopathogenesis, diagnosis, classification, and appropriate management.

AFRS, in its strictest sense, is defined in a patient who is immunocompetent and with an allergy to fungus. The most common fungi reported are the dematiaceous species, e.g. Biploaris, Curvularia, Alternaria, Aspergillus.³ The overall incidence of AFRS is 5–10% of patients undergoing surgery for chronic rhinosinusitis.⁴,⁵ Patients who are afflicted are typically young (mean age at diagnosis, 21.9 years), atopic, and immunocompetent, who report long-standing chronic sinusitis despite prolonged medical therapy and multiple surgeries.⁶ AFRS can be considered a refractory, more-severe form of chronic sinusitis. Masterson et al.,⁷ in their retrospective review of 250 patients, found higher rates of revision surgeries in AFRS and chronic sinusitis with patients with polyposis compared with patients with chronic sinusitis without nasal polyposis, the difference being almost threefold, which thus highlights the spectrum of severity.

The pathogenesis of AFRS is not yet fully understood and is a subject of controversy. The immunologic theory presented by Manning and Holman⁸ proposed a cycle of initial antigenic stimulus, followed by hypersensitivity reactions, viz., Gell and Coombs types I and III, and a
resultant self-perpetuating cycle of inflammation, obstruction of sinus ostia, and continuous antigenic exposure. This theory supports the allergic response of individuals susceptible to fungi. Stewart and Hunsaker analyzed fungal-specific immunoglobulin E (IgE) and IgG levels in the controls who were nonatopic, patients with allergic rhinitis, non-allergic fungal rhinosinusitis polyposis, patients with AFRS-like disease, and patients with AFRS. They also found increased levels of serum IgE and IgG to multiple fungi in patients with AFRS and patients with AFRS-like disease.

However, it was subsequently noted that some patients with the clinical picture of AFRS do not have allergies. This, along with the finding that fungi are ubiquitously present in the nose and paranasal sinuses, as suggested by Ponikau et al., raised the question as to why only some individuals develop AFRS and others do not. One plausible explanation to this involves an essential component of AFRS: hypersensitivity to environmental fungal allergens. Collins et al. proposed a theory that AFRS is the result of a local, not systemic, hypersensitivity reaction. This study, which was based on finding fungus-specific IgE in the mucin of patients with AFRS as well as patients without AFRS, proposed evidence for a local type I response.

There are recent data that fungal proteases, which are an essential part of fungal physiology and development, are present in most airborne particles and can activate and enhance the innate immune response, which results in IgE-induced inflammation. These fungal proteases mediate their actions by acting on protease-activated receptors (PAR), which are a family of proteolytically activated 7-transmembrane G protein coupled receptors that are widely expressed in airway epithelium, mast cells, eosinophils, neutrophils, macrophages, lymphocytes, smooth muscle, endothelium, fibroblasts, and neurons. Cleavage within the extracellular amino terminus of these receptors activates them, which leads to G-signaling cascades that increase intracellular phospholipase C, which results in increased intracellular Ca\(^{2+}\) levels and eventually secretion and degranulation, which, in turn, promotes edema and angiogenesis. PARs are of four types, viz., PAR1, PAR2, PAR3, and PAR4, based on their structure as revealed by molecular cloning. Genes encoding for PAR1, PAR2, and PAR3 are present on the long arm of chromosome 5, whereas the PAR4 gene is located on the short arm of chromosome 19. Although the location of the four genes differs, there is high degree of structural similarity among them.

Even though the role of PARs in platelet activation and inflammation per se is well established, the significance in local hypersensitivity in airway inflammation is still a matter of active research. Park et al. demonstrated increased airway allergic activity in the form of increased expression of chemokine genes in mouse lung epithelial cells after inoculation of mice with acanthamoeba trophozoites, which possess strong protease activity. Zhang et al. extensively reviewed the role of PARs in allergic inflammation, and, in their review article, described the increased expression of all four PARs in mast cells, whereas PAR2 seemed to be the major influence in directing eosinophil functions. Despite extensive research, there is still an incomplete understanding of the pathophysiology of AFRS. Fungal proteases could play a role in susceptible individuals by activating PARs expressed in the nasal mucosa. There is no evidence yet that directly links the involvement of PARs in the pathogenesis of AFRS. We hypothesize that susceptible individuals overexpress the PARs in their airway epithelium. Protease inhibitors and PARs antagonists could prove to be an effective treatment for AFRS in the future.

**METHODS**

The study was conducted in the Department of Otolaryngology and Head and Neck Surgery, in collaboration with the Department of Biochemistry, Post Graduate Institute of Medical Education and Research, Chandigarh. Institutional ethics committee approval was obtained before commencement of the study (Ref. NK/1753/MS/10589–90). Fifty-one patients, 25 cases and 26 controls, were included in the study. Patients diagnosed as having AFRS in a postoperative biopsy sample on histopathologic examination and who fulfilled all major parameters of the Bent and Kuhn criteria, viz., type I hypersensitivity, nasal polypsis, characteristic CT findings, eosinophilic mucin without invasion, and positive fungal stain, were included. All biopsy samples in this study were evaluated by the same pathologist. The presence of allergic mucin, noninvading fungal hyphae, and eosinophilic inflammation were the necessary parameters for a histopathologic diagnosis of AFRS. For the control group, patients who were undergoing endoscopic sinus surgery for chronic rhinosinusitis with or without nasal polyposis were enrolled. Patients with Kartagener syndrome, cystic fibrosis, primary ciliary dyskinesia, immunodeficiency, HIV, concomitant autoimmune diseases, sinonasal malignancies, and invasive fungal sinusitis were excluded from the study.

All the patients were initially given a trial of maximal medical management in the form of steroid nasal sprays, antihistaminics, and oral steroids in tapering doses in refractory cases, and those who had persistence of disease were taken for surgery after providing well-informed consent. All the patients in both the groups were given an additional course of 0.5 mg/kg body weight oral prednisolone for a week before the surgery. Patients suspected of having AFRS underwent Aspergillus-specific skin-prick testing and Aspergillus-specific IgE testing to augment the diagnosis. During
surgery, mucosal biopsy samples were taken from the anterior ethmoid sinuses in all the patients and were stored in RNaLater (Invitrogen, Thermofisher Scientific, Waltham, MA) at −80°C until additional experiments were conducted. Tissue, 15–30 mg of each sample, was transferred to a 1.5-mL microcentrifuge tube that contained 500 μL of TRIzol reagent (Life Technologies Pvt Ltd, Carlsbad, CA). The samples were homogenized by using disposable homogenizer probes and were incubated at room temperature for complete dissociation of the nucleoprotein complex. By using the TRIzol method according to the manufacturer’s protocol, messenger RNA (mRNA) was isolated. The RNA was quantified by measuring absorbance at 260 nm with a Picodrop instrument (Picodrop Ltd., Cambridge, U.K.). RNA integrity was checked by running the samples on 2% agarose gel; 1–2 μg of RNA was treated with DNase 1 kit (Thermo Fisher Scientific, Waltham, MA) to remove any DNA contamination. RNA was then reverse transcribed by following the protocol of Verso complementary DNA synthesis kit (Thermo Fisher Scientific). Integrity of the complementary DNA was confirmed by checking for the expression of the housekeeping gene β-actin. Each of the four genes were amplified by using specific primers, designed by using the NCBI/primer-BLAST (National Centre for Biotechnology Information/primer-Basic Local Alignment Search Tool) software and synthesized commercially. Polymerase chain reaction (PCR) was performed by following optimized assay in a thermal cycler: a denaturation program (95°C for 10 minutes), an amplification program was repeated for 36 cycles (94°C for 30 seconds, 60°C for 30 seconds, 72°C for 30 seconds), and a final extension (72°C for 10 minutes). The amplified products were run on 1.8% agarose gel and, finally, quantified by densitometry and calculated by using imageJ software. All values were normalized to the expression of β-actin.

The raw data obtained were subjected to statistical analysis.

Statistical Analysis

The statistical analysis was carried out by using Statistical Package for Social Sciences (SPSS for Windows, SPSS Inc., Chicago). Normality of the quantitative data was assessed by using the Kolmogorov-Smirnov test. The various parameters for the two groups were compared by using the Mann-Whitney test. The comparison of genes between each within the two groups was performed by using the Wilcoxon signed rank test. A p value of <0.05 was considered to be statistically significant in all the tests.

RESULTS

In the test population, of a total number of 25 subjects, 15 were male and 10 were female subjects, and, in the control population, the total number of subjects was 26, 13 of whom were male and 13 were female subjects (Table 1). The mean age of the 25 subjects in the test population was 27.16 ± 12.87 years, whereas that of the 26 patients of the control population was 39.7 ± 17.35 years (Table 1). Eleven of 25 patients (44%) in the test group and 6 of 26 subjects (23.07%) in the control group had a history of asthma (Table 1). Aspergillus-specific skin-prick testing was performed only in patients who were clinically and radiologically suspected to have AFRS, and 15 patients in the AFRS group exhibited a positive response, 4 did not surmount a type-1 reaction, and 5 patients did not undergo the test due to logistic issues.

Representative gel images of the bands obtained for the four PAR genes are depicted in Figs. 1–4. Sample numbers 26 and 27 (controls) were excluded from the study because no RNA could be isolated from them. Ten samples (all controls) were excluded from PAR4 analysis only.

|                                | Test Group, AFRS (n = 25) | Control Group, CRS (n = 26) | p Value |
|--------------------------------|---------------------------|-----------------------------|---------|
| Age, mean ± SD, y              | 27.16 ± 12.87             | 39.7 ± 17.35                | 0.0052  |
| No. males to females           | 15:10                     | 13:13                       | 0.4731  |
| Asthma, no./total no. (%)      | 11/25 (44)                | 6/26 (23.07)                | 0.1131  |
| Skin-prick testing result, no. |                           |                             | —       |
| Positive                       | 15                        | Not determined              | —       |
| Negative                       | 4                         |                             | —       |
| Not determined                 | 5                         |                             | —       |
| Peripheral eosinophilia, mean ± SD | 6.32 ± 2.93              | 4.34 ± 1.89                 | 0.0059  |
| Lund-Mackay score, mean ± SD   | 18.56 ± 6.93              | 8.46 ± 6.33                 | 0.0001  |

AFRS = Allergic fungal rhinosinusitis; CRS = chronic rhinosinusitis; SD = standard deviation.

Bold values indicated p < 0.05.
controls for all four PAR genes was statistically significant only for PAR1 (p = 0.007), PAR1 and PAR2 (p = 0.0001), PAR2 and PAR4 (p = 0.002), and PAR3 and PAR4 (p = 0.009) in the test group (Table 3). PAR1 was observed to be significantly more expressed than the other PAR genes, whereas PAR4 was found to be the least expressed. In the control group, as well, PAR1, PAR2, and PAR3 exhibited higher expression compared with PAR4 but achieved a statistically significant difference between PAR3 and PAR4 genes only (Table 4). Box plots of the expression of the four PAR genes in both the groups are depicted in Fig. 6.

DISCUSSION

AFRS can be considered a refractory form of chronic rhinosinusitis characterized by intense eosinophilic response, which results in, e.g., allergic mucin, nasal polyps, hypersensitivity. In the most simple terms, it can be defined as an allergic reaction to environmental fungal allergens. However, various studies and evidence over the past 2 decades indicate a more-complex etiology. The role of PARs in airway inflammation has been extensively studied lately and the positive correlate triggered the possibility of a local hypersensitive reaction to fungal proteases, which act through PARs located on the cell membrane of sinonasal epithelium and trigger the inflammatory cascade. They increase the permeability of the surface epithelium by disrupting the tight junctions between epithelial cells, thereby providing access to the allergens. This was supported by the work of Tai et al. who showed the breakdown of occludin, a tight junction protein, by the serine protease of *Penicillium chrysogenum*. Despite all the evidence that favors the role of PARs in the inflammatory pathway, there is a paucity of evidence that directly links AFRS and PAR expression. In our study, we compared the differential expression of the four PAR genes in 25 patients who had AFRS with 26 patients who had chronic rhinosinusitis with or without nasal polyposis.

After analyzing the results statistically, we found an increased expression of all four PAR genes in the test population compared with the controls as observed by the bands obtained on the agarose gels and their respective densitometric values. There was a statistically significant difference in the expression of PAR1 and PAR2 gene expression between the two groups and a borderline significance, with a p value of 0.059 for PAR3. In a study by Ebert et al., PAR expression was compared between patients with AFRS and controls without disease, which included patients who were undergoing endoscopic pituitary surgery, and between patients with AFRS and controls without disease who had chronic rhinosinusitis. It was concluded that a significant difference was seen in PAR3 expression in the AFRS versus the pituitary group. None of the genes in any of the other groups had a statistically significant difference. Although previous studies demonstrated the role of PAR2, primarily in the allergic pathway, there is evidence that PAR3 is similarly

**Figure 1.** Representative agarose gel image for polymerase chain reaction–amplified products of the protease-activated receptor 1 (PAR1) gene. Product size = 209 base pairs (bp). Lane 1: 50-bp ladder; lanes 2–6: control samples; lanes 7–11: test samples.

**Figure 2.** Representative agarose gel image for polymerase chain reaction–amplified products of the protease-activated receptor 2 (PAR2) gene. Product size = 247 base pairs (bp). Lane 3: 50-bp ladder; lanes 1–2: control samples; lanes 4–7: test samples.

**Figure 3.** Representative agarose gel image for polymerase chain reaction–amplified products of the protease-activated receptor 3 (PAR3) gene. Product size = 243 base pairs (bp). Lane 8: 50-bp ladder; lanes 1–3: test samples; lanes 4–7: control samples.

**Figure 4.** A representative agarose gel image for polymerase chain reaction–amplified products of the protease-activated receptor 1 (PAR1) gene. Product size = 150 base pairs (bp). Lane 3: 100-bp ladder; lanes 1–2: test samples; lanes 4–7: control samples.
involved. Shin et al.\textsuperscript{24} demonstrated that nasal epithelial cells did not express PAR mRNA before stimulation; however, after stimulation with fungi, viz., Alternaria, Cladosporium, and Aspergillus, they expressed PAR2 and PAR3 mRNA, as was evident in the reverse transcriptase–PCR analysis.

One possible explanation of conflict of the results with respect to the difference seen in the PAR1 gene could be the difference in the etiologic agent of fungal sinusitis in the Indian subcontinent. Aspergillus flavus is the most commonly isolated species in India compared with the dematiaceous fungi and Aspergillus fumigatus in the West.\textsuperscript{25–27} In our study, 16 of 25 patients in the AFRS group were culture positive, with A. flavus isolated in 13 patients, A. fumigatus in 1 patient, and Alternaria alternata in 2 patients. To our knowledge, there are no data of the interaction of fungal proteases in different fungal species. Another factor that accounted for the difference could be the method of interpretation of gene expression. Although Ebert et al.\textsuperscript{23} used the microarray technique, we performed PCR in our study for this purpose. The increased overall expression of all four pars in the test group, as shown in this study, is consistent with the literature that indicates the presence of PARs on epithelial cells, mast cells, lymphocytes, fibroblasts etc. The increased amount of inflammation, together with the activation of cells by fungal proteases in the test group, could be the reason for an increased expression seen.

However, when the expression of par4 was compared with the other three par genes, it was found to be clearly lower in both the test and the control groups, and the difference was significant in the test group. This was evident in the Wilcoxon signed rank test, in which a statistically significant difference was seen between par1 and par4, par2 and par4, par3 and par4 in the test group. These data also seemed to be consistent with the literature because of all the PARs, PAR4 was the least associated with airway inflammation. In the control group, however, an intergene comparison showed a statistically significant difference only between par3 and par4. This suggested possible upregulation of the other par genes compared with par4 in the test samples. Our study had some limitations. Although it clearly demonstrated a role of PAR expression in AFRS, a larger sample size and further validation of data with more confirmatory methods, e.g., real-time PCR, would be required to conclusively link PAR expression with AFRS.

**CONCLUSION**

This study was undertaken to improve our understanding of AFRS and its pathogenesis. The two major conclusions from our study were the following: first, a statistically increased expression of par1 and par2 in the test group, and, second, a decreased overall expression of par4 compared with the other par genes in both the groups. Presently, there are limited options available to control the intense inflammatory response that occurs in this disease. PAR antagonists, by causing a disruption in this inflammatory pathway, could help in better

| Serial No. | Gene Name | Case Group | Control Group | p Value |
|------------|-----------|------------|---------------|---------|
| 1          | par1      |            |               |         |
|            | No.*      | 25         | 24            | 0.004   |
|            | Median (IQR) | 0.21 (0.04–0.57) | 0.0 (0.0–0.21) |
|            | Min-max   | 0.0–1.65   | 0.0–0.86      |         |
| 2          | par2      |            |               |         |
|            | No.*      | 25         | 24            | 0.050   |
|            | Median (IQR) | 0.03 (0.0–0.45) | 0.0 (0.0–0.12) |
|            | Min-max   | 0.0–0.97   | 0.0–0.65      |         |
| 3          | par3      |            |               |         |
|            | No.*      | 25         | 24            | 0.059   |
|            | Median (IQR) | 0.05 (0.0–0.44) | 0.0 (0.0–0.04) |
|            | Min-max   | 0.0–2.09   | 0.0–1.48      |         |
| 4          | par4      |            |               |         |
|            | No.*      | 25         | 14            | 0.087   |
|            | Median (IQR) | 0.0 (0.0–0.07) | 0.0 (0.0–0.0) |
|            | Min-max   | 0.0–0.28   | 0.0–0.97      |         |

**Table 2** Mann-Whitney test for the four genes, comparing each of their expressions in the two groups.

par = Protease-activated receptor; IQR = interquartile range; min = minimum; max = maximum.

*The number of subjects analyzed in each group.

Bold values indicated p < 0.05.
Figure 5. Box plots, depicting the comparison of the four genes in the two groups; it can be seen that the expression of all four genes is higher in the case allergic fungal rhinosinusitis (AFRS) group.

Table 3 Wilcoxon signed rank test, depicting intergene comparison within the case group

| Serial No. | Gene Name | p Value |
|------------|-----------|---------|
| 1          | par1      | 0.007   |
|            | par2      |         |
| 2          | par1      | 0.029   |
|            | par3      |         |
| 3          | par1      | 0.0     |
|            | par4      |         |
| 4          | par2      | 0.314   |
|            | par3      |         |
| 5          | par2      | 0.002   |
|            | par4      |         |
| 6          | par3      | 0.009   |

*par = Protease-activated receptor.* Bold values indicated $p < 0.05$.

Table 4 Wilcoxon signed rank test, depicting intergene comparisons within the control group

| Serial No. | Gene Name | p Value |
|------------|-----------|---------|
| 1          | par1      | 0.345   |
|            | par2      |         |
| 2          | par1      | 0.209   |
|            | par3      |         |
| 3          | par1      | 0.069   |
|            | par4      |         |
| 4          | par2      | 0.363   |
|            | par3      |         |
| 5          | par2      | 0.139   |
|            | par4      |         |
| 6          | par3      | 0.018   |

*par = Protease-activated receptor.* Bold values indicated $p < 0.05$. 
medical management of AFRS and result in fewer relapses.

ACKNOWLEDGMENTS

We thank Stuti Agarwal, Ph.D., Department of Biochemistry, Post Graduate Institute of Medical Education and Research, Chandigarh, for her valuable support and guidance during the laboratory procedures.

ETHICAL APPROVAL

This study was approved by our institute’s Ethics Committee (Ref:NK/1753/MS/10589-90).

STATEMENT OF HUMAN AND ANIMAL RIGHTS

This study does not contain any animal subjects and the patients were duly enrolled in the study after a well informed consent.

STATEMENT OF INFORMED CONSENT

All patients signed a consent form and were explained in detail about their participation before being enrolled in this study.

REFERENCES

1. Robson JM, Hogan PG, Benn RA, Gatenby PA. Allergic fungal sinusitis presenting as a paranasal sinus tumour. Aust N Z J Med. 1989; 19:351–353.
2. Kuhn FA, Javer AR. Allergic fungal rhinosinusitis: Our experience. Arch Otolaryngol Head Neck Surg. 1998; 124:1179–1180.
3. Katzenstein AL, Sale SR, Greenberger PA. Allergic Aspergillus sinusitis: A newly recognized form of sinusitis. J Allergy Clin Immunol. 1983; 72:89–93.
4. Morpeth JF, Rupp NT, Dolen WK, et al. Fungal sinusitis: An update. Ann Allergy Asthma Immunol. 1996; 76:128–139; quiz 139–140.
5. Thrasher RD, Kingdom TT. Fungal infections of the head and neck: An update. Otolaryngol Clin North Am. 2003; 36:577–594.
6. Ryan MW, Marple BF. Allergic fungal rhinosinusitis: Diagnosis and management. Curr Opin Otolaryngol Head Neck Surg. 2007; 15:18–22.
7. Masterson L, Egro FM, Bewick J, et al. Quality-of-life outcomes after sinus surgery in allergic fungal rhinosinusitis versus nonfungal chronic rhinosinusitis. Am J Rhinol Allergy. 2016; 30:e30–e35.
8. Manning SC, Holman M. Further evidence for allergic pathophysiology in allergic fungal sinusitis. Laryngoscope. 1998; 108: 1485–1496.
9. Stewart AE, Hunseker DH. Fungus-specific IgG and IgE in allergic fungal rhinosinusitis. Otolaryngol Head Neck Surg. 2002; 127:324–332.
10. Ponikau JU, Sherris DA, Kern EB, et al. The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin Proc. 1999; 74:877–884.
11. Collins M, Nair S, Smith W, et al. Role of local immunoglobulin E production in the pathophysiology of noninvasive fungal sinusitis. Laryngoscope. 2004; 114:1242–1246.
12. Reed CE. Inflammatory effect of environmental proteases on airway mucosa. Curr Allergy Asthma Rep. 2007; 7:368–374.
13. Yike I. Fungal proteases and their pathophysiological effects. Mycopathologia. 2011; 171:299–323.
14. Berger P, Tunon-De-Lara JM, Savineau JP, Marthan R. Selected contribution: Tryptase-induced PAR-2-mediated Ca(2+) signaling in human airway smooth muscle cells. J Appl Physiol. 2001; 91: 995–1003.
15. Coughlin SR, Camerer E. PARticipation in inflammation. J Clin Invest. 2003; 111:25–27.
16. Miike S, Kita H. Human eosinophils are activated by cysteine proteases and release inflammatory mediators. J Allergy Clin Immunol. 2003; 111:704–713.
17. Ossovskaya VS, Bunnett NW. Protease-activated receptors: Contribution to physiology and disease. Physiol Rev. 2004; 84:579–621.
18. Kahn ML, Hammes SR, Botka C, Coughlin SR. Gene and locus structure and chromosomal localization of the protease-activated receptor gene family. J Biol Chem. 1998; 273:23290–23296.

19. Xu WF, Andersen H, Whitmore TE, et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A. 1998; 95:6642–6646.

20. Park MK, Cho MK, Kang SA, et al. Acanthamoeba protease activity promotes allergic airway inflammation via protease-activated receptor 2. PLoS One. 2014; 9:e92726.

21. Zhang H, Zeng X, He S. Evaluation on potential contributions of protease activated receptors related mediators in allergic inflammation. Mediators Inflamm. 2014; 829068.

22. Tai HY, Tam MF, Chou H, et al. Pen ch 13 allergen induces secretion of mediators and degradation of occludin protein of human lung epithelial cells. Allergy. 2006; 61:382–388.

23. Ebert CS Jr, McKinney KA, Urrutia G, et al. Expression of protease-activated receptors in allergic fungal rhinosinusitis. Int Forum Allergy Rhinol. 2014; 4:266–271.

24. Shin SH, Lee YH, Jeon CH. Protease-dependent activation of nasal polyp epithelial cells by airborne fungi leads to migration of eosinophils and neutrophils. Acta Otolaryngol. 2006; 126:1286–1294.

25. Dhiwakar M, Thakar A, Bahadur S, et al. Preoperative diagnosis of allergic fungal sinusitis. Laryngoscope. 2003; 113: 688–694.

26. Chakrabarti A, Sharma SC, Chandler J. Epidemiology and pathogenesis of paranasal sinus mycoses. Otolaryngol Head Neck Surg. 1992; 107:745–750.

27. Panda NK, Sharma SC, Chakrabarti A, Mann SB. Paranasal sinus mycoses in north India. Mycoses. 1998; 41:281–286.